Fundraising in the Chinese healthcare sector is expected to reach a new record in 2025, with year-to-date figures reaching $10.6 billion, more than the combined total from 2022 to 2024, the South China Morning Post reported Wednesday, citing Dealogic.

Among the noteworthy transactions are Wuxi AppTec's (HKG:2359, SHA:603259) $980-million share placement in Hong Kong, Hansoh Pharmaceutical Group's (HKG:3692) $500-million new share issuance, Akeso's (HKG:9926) $449-million fundraising, and Innovent Biologics' (HKG:1801) $548-million fundraiser.

On the IPO front, Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) offering was one of Hong Kong's largest, with $1.3 billion raised in May, the report said.

Citigroup expects more issuances worth "several billion more" in the second half, the SCMP said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)